NT-PGC1-α Promotes Hepatic Lipid Metabolism Without Increasing Gluconeogenesis | 14801
Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
PGC-1α (PPARγcoactivator 1α) can promote the transcription of related target genes by interaction with many nuclear
receptors. In muscle cells and adipocytes, PGC-1α functions as glucose and fat metabolism promotor. NT-PGC1-α, an isomer
of PGC-1α is reported by Zhang for the first time in 2009. Since it lacks the structural domain to interact with FOXO1, which
facilitates gluconeogenesis, we came up with a new assumption which is that NT-PGC-1α can enhance fatty acid oxidation
in liver, yet has no influence on hepatic gluconeogenesis. By the overexpression of NT-PGC-1α in hepatic cell system HepG2
and L02, it was proved that NT-PGC-1α cannot promote the expression of PEPCK (phosphoenolpyruvate carboxykinase, a
key enzyme in gluconeogenesis process) and the hepatic production of glucose, but sharply induced the expression of CPT1A
(carnitine palmitoyltransferase 1A, a key enzyme in fatty acid oxidation). Mouse primary hepatocytes induced by palmitate or
FGF21 showed notably increased expression of NT-PGC-1α. We then treated mice models of alcoholic fatty liver with resveratrol,
and the expression of NT-PGC-1α increased remarkably. This showed that NT-PGC-1α is involved in the process of resveratrol
regulating hepatic fatty acid metabolism and proved that NT-PGC-1α participate in hepatic fatty acid metabolism in animals. In
this case, the relation between NT-PGC-1α and hepatic fatty acid metabolism is discussed in cells and in animals, and has proved
that NT-PGC-1α can enhance fatty acid oxidation in liver, yet has no influence on hepatic gluconeogenesis. According to these
findings, NT-PGC-1α could be a new target in obesity or type 2 diabetic treatment.
Qiang Xiao-Yan received her bachelor?s degree in Bioengineering at China Pharmaceutical University in 2010. With 2-years school-enterprise
training, she finished her master?s degree in advance in 2012. She is currently working as a Ph.D. student in Biochemical Pharmacy at China
Pharmaceutical University. To date, she has published several papers in state core journals in China.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals